Yelak Biru/LinkedIn
Jun 16, 2025, 16:24
Yelak Biru: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, posted on X:
“Congratulations Dr. Kaur on this iMMagine-1 study result and presentation at EHA 2025
‘Anito-cel utilizes a novel, synthetic antigen-binding domain called the D-Domain, which allows for high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. Coupled with a fast off rate and ability to detach from the BCMA target, [this provides] us with a safe and efficacious product,’ lead study author Gurbakhash Kaur said during the presentation.
-
Anito-cel achieved a 97% overall response rate in relapsed/refractory multiple myeloma patients with at least three prior therapies, with a stringent complete response rate of 68%.
-
The novel D-Domain in anito-cel enhances transduction efficiency and safety, contributing to its efficacy in the iMMagine-1 trial.
-
Safety data showed manageable cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, with most cases resolving quickly.
-
Anito-cel is being further evaluated in the phase 3 iMMagine-3 trial against standard-of-care therapy for relapsed/refractory multiple myeloma.”
Title: Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
Author: Chris Ryan
Read The Full Article at OncLive25.
Find More Posts on Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera